SAGE Live signals | Maximize Profits with Getagraph.com

BUY 135548 min ago

@ $26.76

Issued: 14 Feb 2024 @ 12:06

Return: -56.28%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 6.23 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	917 876
Average Volume	1.01M
Market Cap	704.13M
EPS	$0 ( 2024-05-07 )
Next earnings date	( $-1.690 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.390
ATR14	$0.0120 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-13	Greene Barry E	Buy	168 000	Stock Option (Right to Buy)
2024-02-13	Cook Anne Marie	Buy	11 250	Common Stock
2024-02-13	Cook Anne Marie	Buy	22 500	Stock Option (Right to Buy)
2024-02-13	Gault Laura	Buy	22 500	Stock Option (Right to Buy)
2024-02-13	Gault Laura	Buy	11 250	Common Stock

INSIDER POWER
92.98
Last 97 transactions
Buy: 1 228 960 \| Sell: 86 892

Volume Correlation

Long: 0.07 (neutral)

Short: 0.59 (weak)

Signal:(48.393) Neutral

SAGE Therapeutics Inc Correlation

10 Most Positive Correlations
FXNC	0.957
SFST	0.948
WKME	0.946
NLSP	0.945
HAIN	0.943
SIRI	0.942
WNEB	0.941
LCFY	0.939
AUVI	0.937
PEV	0.936

10 Most Negative Correlations
IXAQ	-0.949
KALU	-0.949
VITL	-0.947
PWP	-0.945
SLAM	-0.932
VCTR	-0.932
PRIM	-0.93
GGAL	-0.929
NKTR	-0.928
RZLT	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SAGE Therapeutics Inc Correlation - Currency/Commodity

0.42
( neutral )

0.47
( neutral )

0.00
( neutral )

-0.52
( weak negative )

-0.33
( neutral )

-0.27
( neutral )

SAGE Therapeutics Inc Financials

Annual	2023
Revenue:	$86.46M
Gross Profit:	$84.30M (97.50 %)
EPS:	$-9.05

FY	2023
Revenue:	$86.46M
Gross Profit:	$84.30M (97.50 %)
EPS:	$-9.05

FY	2022
Revenue:	$7.69M
Gross Profit:	$6.87M (89.42 %)
EPS:	$-8.49

FY	2021
Revenue:	$6.31M
Gross Profit:	$5.76M (91.23 %)
EPS:	$-7.80

Financial Reports:

No articles found.

SAGE Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

SAGE Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.